JPRN-UMIN000007510已完成2 期
A phase 2 study of weekly Nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer - A phase 2 study of weekly Nab-Paclitaxel followed by FEC as primary therapy for operable breast cancer
ahanishi Clinic0 个研究点目标入组 30 人开始时间: 2012年3月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Cases with prior history of hypersensitivity reaction to the drugs or solvents (e.g. albumin, paclitaxel) used in this protocol. 2. Bilateral breast cancer cases. 3. Cases with inflammatory breast cancer. 4. Male breast cancer cases. 5. Cases with active secondary malignancy (current secondary malignancy or other malignancy within 5 years) . 6. Cases with conditions with the potential to compromise the planned treatment, such as cases with active infection, diarrhea, intestinal paralysis, intestinal obstruction, uncontrolled diabetes, uncontrolled angina and myocardial infarction within 6 months, heart failure, and other serious conditions. 7. Pregnant or breast feeding cases. 8. Cases with pulmonary fibrosis or interstitial pneumonia. 9. Cases with severe myelodepression, renal or liver dysfunction. 10. Cases in which the treating physician deems inappropriate to be entered into this study for other reasons.
研究者
相似试验
招募中
不适用
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast CancerBreast cancerJPRN-UMIN000005979Wakayama Medical University50
已完成
2 期
Phase II study of weekly nab-paclitaxel in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.JPRN-UMIN000013390ational Hospital Organization Asahikawa Medical center40
招募中
不适用
Phase II trial of weekly Nab-Paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer.Advanced Gastric CancerJPRN-UMIN000015968Tottori University35
已完成
2 期
Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)Primary breast cancerJPRN-UMIN000001205Saitama Breast Cancer Clinical Study Group (SBCCSG)63
招募中
2 期
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapyMetastatic and Recurrenced Breast CancerJPRN-UMIN000009153Toho University Omori Medical Center20